Skip to content
Catalyst

PapersPMID:33030563

The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial.

Osteoporosis international2021The record ↗

  1. Finding, very limited evidencelowersSerum undercarboxylated osteocalcin concentration

What moved

1 findingHow to read these marks →
  • “Undercarboxylated osteocalcin decreased in the MK-7-group (- 65.2 ± 23.5%) (mean ± SD) compared with the placebo group (- 0.03 ± 38.5%), p < 0.01 after 1 year.”
    Study
    RCT
    Duration
    12 months
    Dose studied
    MK-7 375 µg once daily, added to vitamin D3 38 µg/day and calcium 800 mg/day given to both arms
    Population
    postmenopausal women with osteopenia, both arms receiving vitamin D3 38 µg/day and calcium 800 mg/day; result at 1 year of a 3-year trial

Study record

Design
randomised controlled trial
Species
human
Population
postmenopausal women with osteopenia
Participants
142
Comparator
placebo
Duration
1,096 days
Endpoints measured
8